Plain-English translation of NCT06092957 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether patients with advanced nasopharyngeal cancer (a type of throat cancer) who have a complete response to initial chemotherapy combined with immunotherapy can safely receive lower-dose radiation therapy instead of the standard higher dose. You would be randomly assigned to one of three treatment groups: lower-dose radiation alone, lower-dose radiation plus chemotherapy, or standard-dose radiation plus chemotherapy.
Doctors want to know if reducing radiation doses can maintain good outcomes while potentially causing fewer side effects and long-term complications for patients whose cancers have already responded very well to the initial chemotherapy and immunotherapy combination.
You likely qualify if…
You likely don't qualify if…
After completing your initial 3 cycles of chemotherapy and immunotherapy, you will be randomly assigned to receive one of three radiation treatment approaches over several weeks. Depending on which group you're in, you'll either receive 30 sessions of lower-dose radiation alone, 30 sessions of lower-dose radiation combined with chemotherapy, or 33 sessions of standard-dose radiation combined with chemotherapy. You'll have regular follow-up visits to monitor your response and watch for any side effects.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China